DEPO Depomed, Inc. (delisted)

Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first-quarter 2018 financial results on Thursday, May 10, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results.

Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

Audio Conference Call:

U.S. Dial-in Number:	1-877-326-2337
International Dial-in Number:	1-631-456-4258
Conference ID:	1328285277

An archived webcast replay will be available on the Company's website for three months.

About DepomedDepomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com. 

INVESTOR AND MEDIA CONTACTS:

John B. Thomas SVP, Investor Relations and Corporate Communications jthomas@depomed.com